Compare CHPT & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHPT | TNYA |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.0M | 168.2M |
| IPO Year | 2019 | 2021 |
| Metric | CHPT | TNYA |
|---|---|---|
| Price | $5.70 | $0.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $9.25 | $5.33 |
| AVG Volume (30 Days) | 346.6K | ★ 2.0M |
| Earning Date | 06-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $411,224,000.00 | N/A |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | $16.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.44 | $0.53 |
| 52 Week High | $12.61 | $2.35 |
| Indicator | CHPT | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 38.79 |
| Support Level | $5.64 | $0.65 |
| Resistance Level | $6.60 | $0.81 |
| Average True Range (ATR) | 0.28 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 27.29 | 9.97 |
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.